Renal Transplantation in the Elderly - nEverOld Study
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
An exploratory study of the efficacy and safety of a regimen consisted of Everolimus plus low
tacrolimus for the immunosuppression in renal transplantation in the elderly.
To evaluate the pharmacokinetics of immunosuppressants that have been little studied in this
population.
To evaluate whether the polymorphism of the genes that determine the expression of
metabolizing enzymes and transporters of xenobiotics interfere in the elderly, also in the
younger population, absorption and metabolism of immunosuppressants.
To evaluate the potential minimization of immunosuppression in this population refers to how
does the re-population of peripheral lymphocytes, in this age group, after the use of
lymphocyte-depleting agents such as thymoglobulin and subsequently maintained with two
regimes.
Clarify which markers of renal filtration exist today, cystatin C and serum creatinine, is
the right to monitor renal function in elderly transplanted.